Emerging Treatment Options for RET-Driven Non-Small Cell Lung and Thyroid Cancers: Preparing Pharmacists to Optimize Patient Care
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Lilly USA, LLC.
R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Professor, Department of Hematology and Medical Oncology and
Department of Pharmacology and Chemical Biology
Emory University School of Medicine
Director, Phase l Clinical Trials Section
Larry Rosenberg, medical writer.
Dr. Harvey has disclosed that his institution has received research funding that supports his salary from the following: Abbisko, AbbVie, Actuate, Alkermes, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Biomedical, Calithera, Five Prime Therapeutics, FlexBio, FujiFilm, Genmab, GlaxoSmithKline, Halozyme, Incyte, Infinity, InhibRx, Lycera, Merck, Meryx, Nektar, Pfizer, Puma, RAPT Therapeutics, Regeneron, Rgenix, Sanofi, Seattle Genetics, Sutro, Takeda, and Xencor; and has served as a consultant for Bristol-Myers Squibb, GlaxoSmithKline and Takeda.
The writer, Larry Rosenberg, has disclosed that he has no actual or potential conflict of interest in relation to this program.
The clinical reviewer, Megan May, PharmD, BCOP, has no relevant affiliations or financial relationships with a commercial interest to disclose.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 2.0 hour (0.2 ceu)
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes
September 30, 2020
September 30, 2021
This accredited activity has been designed to meet the educational needs of oncology, managed care and specialty pharmacists nationwide.
HOW TO OBTAIN CREDIT
During the period September 30, 2020 through September 30, 2021 participants must 1) read the learning objectives and faculty disclosures; 2) listen/view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
To inform and educate oncology, managed care and specialty pharmacists on the optimal and emerging treatment options of adult patients with RET-driven NSCLC and thyroid cancer, such that they can optimize patient care and support the healthcare team in a cost-effective manner.
At the conclusion of the activities the learner will be able to:
- Identify current and novel treatment options in RET-driven NSCLC and thyroid cancer and how they differ from those for treating other types of NSCLC and thyroid cancers
- Appraise the importance of integrating new and/or emerging therapies for treatment of RET-driven NSCLC and thyroid cancer into the current treatment paradigm
- Formulate approaches to provide appropriate access to treatment by determining optimal therapy recommendations based on patient specific factors
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Lilly USA, LLC. Daiichi Sankyo, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care
professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing
education for the broad spectrum of health care professionals. This site features a searchable database of accredited
Power-Pak C.E.® courses on important topics for today's health care professionals.
PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants
may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates
for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new
courses available on the site.